ArticleAntibody therapeutics2023

Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305.

Zhouyi Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.